Scholars Central

Conference abstractPublished 20 Sep 2017

Clinical trials in cystic fibrosis patients; does tachycardia matter?: A case report

Authors: Khalid Abou Farha

Clinical Pharmacology Research Centre, UK

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Clinical trials in cystic fibrosis (CF) patients might include post-B2 agonist bronchodilator (e.g. Salbutamol) evaluation of pulmonary functions. Sinus and SVT tachycardia have known dose-related side effects of inhaled salbutamol. A relationship between inhaled beta 2 agonists and increased risk of myocardial ischemia (MI) and infarction has been reported. Under normal breathing conditions, CF patients might show mild tachycardia compared to healthy subjects. Nevertheless, the impact of B2 agonists on the CF- associated tachycardia is often an ignored safety parameter in CF clinical trials. Here, we demonstrate a case of post-salbutamol clinically significant tachycardia associated with ECG features of MI in a CF patient. Case Report: A 21 year old CF female patient has been included in a clinical trial evaluating a new medication for the treatment of CF. Medical history, physical examination, vital signs and laboratory investigations showed no clinically relevant findings. A 12- leads ECG recording showed a sinus rhythm with a heart rate (HR) of 90 bpm. An inhalation dose of 400ug salbutamol has been administered to perform post bronchodilator (PBD) pulmonary function tests and collect spontaneously expectorated sputum. The patient’s cardiac electrical activity was monitored (by means of telemetry) before (baseline, BL) and after salbutamol administration. A pre-bronchodilator (Pre-BD) telemetric recording showed episodes of asymptomatic tachycardia with fluctuating resting heart rate between 79 to 117 bpm, without ECG signs of myocardial ischemia. At 45-60 minutes after salbutamol administration, the telemetric recordings showed sinus tachycardia with resting HR fluctuating between 97 to 141 bpm and ECG manifestation of tachycardia-induced myocardial ischemia (Figures 1 and 2). 3 to 4 hours post salbutamol the HR returned to BL, and the patient has been discharged after ensuring her safety. Thyroid function tests have been performed to verify the aetiology of the tachycardia. These demonstrated normal results. Re-challenge tests have been performed on other visit. These confirmed the salbutamol associated cardiac effect. Discussion & Conclusion: B2 agonist should be administered with caution to tachycardic CF patients. This may imply salbutamol dose adjustment and requires monitoring with cardiac telemetry. This might avoid unwanted cardiovascular adverse effects such as MI. This line of reasoning is substantiated by the increased likelihood of CF- associated cardiac CFTR chloride channel abnormality that results in deficient CFTR- induced cardiac ischaemic preconditioning and therefore increase the risk for ischemic heart disease in CF patients, particularly in the older age group with pre-existing decreased cardiac reserve.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Khalid Abou Farha”